期刊文献+

肥胖与卵巢癌生存的研究进展

下载PDF
导出
摘要 肥胖的发病率在全球范围内不断上升,与包括卵巢癌在内的多种癌症的发生与生存有关[1]。因卵巢癌常合并腹水与营养不良,肥胖作为可改变的预后因素,是否影响卵巢癌生存,目前尚存在争议。本文就肥胖与卵巢癌化疗、手术及生存方面的相关研究进展进行综述,为后期临床治疗和预防提供理论依据。
机构地区 重庆医科大学
出处 《实用妇科内分泌电子杂志》 2019年第6期18-20,共3页 Electronic Journal of Practical Gynecological Endocrinology
基金 基于大数据的围绝经期综合征诊治辅助支持系统研发(cstc2017shmsA130034) Chk1逆转卵巢癌顺铂耐药的机制研究(2012-2-030)
  • 相关文献

参考文献3

二级参考文献54

  • 1全国肿瘤登记中心.中国肿瘤登记工作指导手册[M].北京:中国协和医科大学出版社,2004.48-50.
  • 2Wang YC, Mcpherson K, Marsh T, et al. Health and economic burden of the projected obesity trends in the USA and the UK[J]. Lancet, 2011, 378(9793): 815-825.
  • 3Vainio H, Bianchini F. Weight control and physical actrivity in cancer prevention[J]. Obes Rev, 2002, 3(1): 5-8.
  • 4Calle EE, Kaaks R. Overweight, obesity and Cancer: epidemiological evidence and proposed mechanisms[J]. Nat Rev Cancer, 2004, 4(8): 579-591.
  • 5Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from Cancer in a prospectively studied cohort of U.S. adults[J]. N Engl J Med, 2003, 348(17): 1625-1638.
  • 6Barrett SV, Paul J, Hay A, et al. Does body mass index affect progression-free or overall survival in patients with ovarian Cancer? Results from SCOTROC I trial[J]. Ann Oncol, 2008, 19(5): 898-902.
  • 7Pinkel D. The use of body surface area as a criterion of drug dosage in Cancer chemotherapy[J]. Cancer Res, 1958, 18(7): 853-856.
  • 8Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing[J]. Invest New Drugs, 2001, 19(2): 171-177.
  • 9Sparreboom A, Wolff AC, Mathijssen RH, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese[J]. J Clin Oncol, 2007, 25(30): 4707-4713.
  • 10DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known[J]. Arch Intern Med, 1916, 5(5): 303-311.

共引文献165

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部